1

COVID-19: impact of original, Gamma, Delta, and Omicron variants of SARS-CoV-2 in vaccinated and unvaccinated pregnant and postpartum women

- 4
- Fabiano Elisei Serra^{1,2,3*}, Elias Ribeiro Rosa Junior⁴, Patricia de Rossi^{2,5}, Rossana
 Pulcineli Vieira Francisco¹, and Agatha Sacramento Rodrigues^{1,4}
- ¹ Department of Obstetrics and Gynecology, University of Sao Paulo (USP), Sao Paulo,
 9 Brazil
- ² Course of Medicine, University of Santo Amaro (UNISA), Sao Paulo, Sao Paulo, Brazil
- ³ Department of Obstetrics, Interlagos Hospital and Maternity, Sao Paulo, Sao Paulo,
 Brazil
- ⁴ Department of Statistics, Federal University of Espirito Santo, Vitoria, Espirito Santo,
- 14 Brazil
- ⁵ Department of Perinatology and Gynecology, Mandaqui Hospital, Sao Paulo, Sao
- 16 Paulo, Brazil
- 17
- 18 ^{*}Corresponding author
- 19 E-mail: fabianoserra@usp.br (ASR)
- 20 Postal address: Universidade de São Paulo, Faculdade de Medicina da Universidade
- de São Paulo. Avenida Dr. Enéas de Carvalho Aguiar, 255 ICHC- 10º andar- sala
 10084
- 23 Cerqueira César CEP 05403-000 São Paulo, SP Brasil
- 24
- 25
- 26 Word count: 2,610
- 27
- 28

2

29 **ABSTRACT**

- 30 Introduction This study compares the clinical characteristics and disease progression
- of vaccinated and unvaccinated pregnant and postpartum women positive for the original, Gamma, Delta, and Omicron variants of severe acute respiratory syndrome
- 33 coronavirus 2 (SARS-CoV-2) using Brazilian epidemiological data.
- 34 Methods Data of pregnant or postpartum patients with coronavirus disease 2019
- 35 (COVID-19) SARS-CoV-2 confirmed using polymerase chain reaction from February
 36 2020 to July 2022 were extracted from a Brazilian national database. The patients were
- 37 divided based on vaccination status and viral variant (original, Gamma, Delta, and
- 38 Omicron). The patients' demographic data, clinical characteristics, comorbidities, signs,
- 39 symptoms, and outcomes were retrospectively compared.
- 40 **Results** Data from 10,003 pregnant and 2,361 postpartum women were extracted from
- 41 the database. Among unvaccinated patients, postpartum women were more likely to be
- admitted to the intensive care unit (ICU). These patients were more likely to require
 invasive ventilation when infected with the original, Gamma, and Omicron variants and
- were more likely to die when infected with the original and Gamma variants. Patientswho were vaccinated had reduced adverse outcomes including ICU admission,
- 46 requirement for invasive ventilation, and death.
- 47 **Conclusion** Postpartum women were more likely to develop severe COVID-19 that 48 required ICU admission or invasive ventilatory support or led to death, among all 49 variants, especially when the patients were unvaccinated. Therefore, the risk of severe 50 COVID-19 should not be underestimated after delivery. Vaccinated patients had a lower 51 risk of severe outcomes. Vaccination should be a top priority in pregnant and 52 postpartum patients.
- 53

54 **KEYWORDS**

- 55 COVID-19, SARS-CoV-2, vaccine, pregnancy, postpartum
- 56
- 57
- 58
- 59

60 WHAT IS ALREADY KNOWN ON THIS TOPIC

- 61 The obstetric population has a higher risk of adverse outcomes due to coronavirus
- disease 2019 (COVID-19). Few studies have compared the outcomes of pregnant and
- 63 postpartum patients or vaccinated and unvaccinated patients; however, no studies have
- 64 separately investigated the effects of each viral variant.

65 WHAT THIS STUDY ADDS

- 66 Postpartum women are more likely to have adverse outcomes, including the 67 requirements for intensive care and invasive ventilation and death, compared with
- 68 pregnant women. Vaccinated women had fewer adverse outcomes. The viral variants
- 69 did not significantly affect the outcomes of these patients.

70 HOW THIS STUDY MIGHT AFFECT RESEARCH, 71 PRACTICE, OR POLICY

- 72 The risks of COVID-19 infection should not be underestimated in postpartum women.
- 73 Postpartum women infected with COVID-19, especially those who are not vaccinated,
- should be monitored carefully. Vaccination should be a top priority in pregnant and
- 75 postpartum women.

4

76 **INTRODUCTION**

Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome
 coronavirus 2 (SARS-CoV-2), which was first reported in Wuhan, China in December

- 79 2019. COVID-19 was declared a pandemic in March 2020.[1] As of 26 August 2022,
- 80 over 596 million cases and 6.4 million deaths have been reported worldwide.[2]
- COVID-19 affects several systems, with a clinical spectrum ranging from asymptomatic to severe and critical disease. Morbidity and mortality among pregnant women and perinatal outcomes are significant concerns. Initial studies did not report a higher mortality rate or more severe disease in obstetric patients with COVID-19; however, later studies reported that obstetric patients had a higher risk of intensive care admission, requiring invasive ventilation, and death, compared with nonpregnant women.[3-11]
- 88 During the course of the pandemic, SARS-CoV-2 developed mutations, resulting in new
- 89 variants. Variants of concern (VOCs) have higher transmissibility, increased virulence,
- 90 and altered COVID-19 epidemiology and presentation. The effectiveness of public
- 91 health, social measures, and available therapeutics decreases for VOCs.[12] As of July
- 92 30, 2022, three VOCs have been detected in Brazil: the Gamma, Delta, and Omicron
- 93 variants.[13]
- A high number of maternal deaths due to COVID-19 has been reported in Brazil, 94 including 124 deaths as of 18 June 2020, [14] and 295 maternal deaths have been 95 confirmed using reverse transcriptase polymerase chain reaction (RT-PCR) as of 2 96 97 January 2021. Puerperal women have a higher risk of serious outcomes (such as 98 intensive care unit (ICU) admission, requirement for invasive and non-invasive 99 ventilatory support, and death) than pregnant women do.[15] The Brazilian Obstetric Observatory for COVID-19 was created on 7 April 2021, and it provides updated data 100 101 released by the Ministry of Health of Brazil. In total, 1,031 maternal deaths due to COVID-19 (including 680 pregnant women and 351 postpartum women) were reported 102 103 in Brazil as of 5 May 2021.[16] Even after vaccination campaigns began for pregnant 104 and postpartum women in Brazil on 1 May 2021, pregnant and postpartum women 105 continued to have higher risks of admission to the ICU, intubation, and death, compared 106 with non-pregnant women and men.[17, 18]
- As vaccination is one of the most effective strategies to reduce the transmission and severity of infectious diseases, it is important to evaluate not only the effectiveness of the vaccines in the obstetric population but also their protection against the new VOCs.[19, 20] Therefore, this study compares the clinical characteristics and outcomes of pregnant and postpartum women based on vaccination status and VOC, using data from a Brazilian national database.
- 113
- 114 **METHODS**

5

115 Patient data were extracted from the System of Information about Epidemiological Surveillance of Influenza (SIVEP-Gripe), a Brazilian national database that includes 116 surveillance data regarding severe acute respiratory syndrome (SARS).[21] Compulsory 117 reporting of SARS due to the flu (acute respiratory conditions, characterized by at least 118 119 two of the following signs and symptoms: fever, chills, headache, sore throat, cough, coryza, anosmia, and ageusia), associated with dyspnoea, persistent chest pressure, 120 121 oxygen saturation $(SpO_2) < 95\%$ on room air, or cyanosis is included in this database. All public and private hospitals must report all hospitalizations and deaths due to SARS-122 123 CoV-2.

124 The SIVEP-Gripe includes demographic data (sex, age, skin colour/ethnicity, level of education, obstetric status, and city of residence), clinical data (signs and symptoms, 125 risk factors, and comorbidities), epidemiological data (previous flu vaccinations, 126 127 community-acquired infection, or nosocomial infection), and laboratory and etiological 128 diagnoses. Hospital and ICU admission, requirement for ventilatory support (invasive or 129 non-invasive), and disease outcome (death or cure) are also reported. SIVEP-Gripe records are publicly-available, anonymized data. Therefore, according to Brazilian 130 Ethics regulatory requirements, ethical approval by an Institutional Review Board was 131 132 not necessary for this study. This study followed the principles of the Declaration of Helsinki. 133

134

135 In this study, the database was searched from 29 December 2019 to 16 July 2022 (epidemiological weeks 1-53 in 2020; 1-52 in 2021; and 1-28 in 2022), as the first 136 137 Brazilian records began in epidemiological week 8 (symptom onset for the first confirmed case of COVID-19 in Brazil occurred on 17 February 2020).[22] The search 138 included all records of obstetric patients aged 10 to 49 years, who were hospitalized 139 with COVID-19 (confirmed using RT-PCR for SARS-CoV-2) (Figure 1). A total of 12,364 140 141 women were divided into two groups: pregnant (n=10,003) and puerperal (n=2,361). Each group was subdivided based on the dominant VOCs in Brazil at the time of 142 diagnosis: original, Gamma, Delta, and Omicron. The Gamma variant was considered 143 dominant from 1 February 2021 to 31 July 2021, the Delta variant from 1 August 2021 144 145 to 31 December 2021, and the Omicron variant from 1 January 2022 to 16 July 146 2022.[13] Vaccination of pregnant and postpartum patients began in May 2021 in Brazil, 147 during the dominance of the Gamma variant.[18] Therefore, patients in the Gamma, 148 Delta, and Omicron subgroups were also divided based on vaccination status. Only 149 valid responses of the analysed variable were considered. The tables of analyses show 150 the number of valid observations for each variable. Variables used in the analysis were 151 age, skin colour/ethnicity, level of education, comorbidities, signs and symptoms, admission to the ICU, requirement for invasive respiratory support, and outcome 152 (death). The reported comorbidities included chronic cardiovascular disease, asthma, 153 154 obesity, and diabetes. The reported signs and symptoms included fever, cough, sore

6

throat, dyspnoea, respiratory discomfort, $SpO_2 < 95\%$ on room air, diarrhoea, vomiting, abdominal pain, fatigue, anosmia, and ageusia.

157 158

159 data analysis

160 Categorical variables are presented as numbers (n) and percentages (%). These were 161 compared using the chi-square or Fisher's exact test. The odds ratio (OR) and 95% 162 confidence interval (CI) were calculated to compare the relative odds of the occurrence 163 of a variable of interest between the groups. All statistical analyses were conducted 164 using R software (version 4.0.3; R Foundation for Statistical Computing Platform).[23]

165

166 **RESULTS**

Data of 12,364 obstetric women (age range: 10-49 years), who were hospitalized with COVID-19 confirmed using RT-PCR for SARS-CoV-2, were included in this study. The pregnant group included 10,003 patients, while the puerperal group included 2,361 patients. Patient age and education level were not significantly different between the groups (Table 1). The rates of the Omicron variant in different ethnic groups were significantly different between the pregnant and puerperal groups. Patients in the puerperal group had fewer comorbidities.

174

Variant	Age (years)	Pregnant	Puerperal	р	
Original	<20	261 (6.9%)	67 (7.2%)		
Original (n=4,741)	20-34	2,526 (66.4%)	596 (63.6%)	0.2567 ^C	
(11=4,741)	≥35	1,017 (26.7%)	274 (29.2%)		
Commo	<20	243 (5.3%)	62 (6.0%)		
Gamma	20-34	2,976 (64.7%)	662 (64.6%)	0.5902 ^C	
(n=5,628)	≥35	1,384 (30.1%)	301 (29.4%)		
	<20	39 (6.8%)	11 (9.6%)		
Delta (n=691)	20-34	391 (67.9%)	75 (65.2%)	0.5666 ^C	
	≥35	146 (25.3%)	29 (25.2%)		
Omicron	<20	85 (8.3%)	30 (10.6%)		
(n=1304)	20-34	722 (70.8%)	189 (66.5%)	0.3260 ^C	
(11-1304)	≥35	213 (20.9%)	65 (22.9%)		
Variant	Skin colour/ethnicity	Pregnant	Puerperal	р	
	White	1,301 (42.1%)	289 (38.6%)		
Original	Black	210 (6.8%)	52 (6.9%)		
Original (n=3,842)	Yellow	38 (1.2%)	3 (0.4%)	0.07546 ^F	
(11=3,042)	Brown	1,531 (49.5%)	401 (53.5%)	-	
	Indigenous	13 (0.4%)	4 (0.5%)		
Gamma	White	1,917 (48.6%)	407 (46.8%)	0.5847 ^F	
(n=4,812)	Black	230 (5.8%)	56 (6.4%)	0.0047	

175 **Table 1. Patient characteristics**

Γ	Yellow	32 (0.8%)	6 (0.7%)	
	Brown	1,754 (44.5%)	397 (45.6%)	
	Indigenous	9 (0.2%)	4 (0.5%)	
	White	242 (48.8%)	50 (51.0%)	
	Black	36 (7.3%)	5 (5.1%)	
Delta (n=594)	Yellow	3 (0.6%)	0 (0.0%)	0.9395 ^F
, ,	Brown	211 (42.5%)	43 (43.9%)	
	Indigenous	4 (0.8%)	0 (0.0%)	
	White	610 (65.9%)	143 (57.0%)	
	Black	50 (5.4%)	10 (4.0%)	
Omicron -	Yellow	9 (1.0%)	0 (0.0%)	0.0039 ^F
(n=1176)	Brown	255 (27.6%)	97 (38.6%)	
	Indigenous	1 (0.1%)	1 (0.4%)	
Variant	Education level	Pregnant	Puerperal	р
	No schooling	7 (0.4%)	3 (0.8%)	4
Original	Up to high school	394 (24.1%)	84 (22.7%)	0.5112 ^F
(n=2,002)	High school	898 (55.1%)	200 (53.9%)	0.0112
(11 2,002)	College	332 (20.4%)	84 (22.6%)	
	No schooling	15 (0.8%)	6 (1.4%)	
	Up to high school	469 (24.3%)	112 (25.8%)	0.4348 ^F
Gamma (n=2,365)	High school	1,051 (54.4%)	236 (54.4%)	0.4040
	College	396 (20.5%)	80 (18.4%)	
	No schooling	0 (0.0%)	0 (0.0%)	
Delta (n=287)	Up to high school	72 (30.1%)	11 (22.9%)	0.5912 ^F
	High school	112 (46.9%)	24 (50.0%)	0.5312
	College	55 (23.0%)	13 (27.1%)	
	No schooling	2 (0.4%)	2 (1.9%)	
	Up to high school	135 (28.2%)	31 (28.9%)	0.3158 [₣]
Omicron	High school	249 (52.0%)	51 (47.7%)	0.5150
(n=586)	College	93 (19.4%)	23 (21.5%)	
Comorbidities	Variant	Pregnant	Puerperal	n
Comorbidities		-	-	p 0.1230 ⁰
Chronic	Original (n=1,889)	239/1,306 (18.3%)	89/583 (15.3%)	0.1230
cardiovascular -	Gamma (n=2,084) Delta (n=256)	245/1,409 (17.4%)	84/675 (12.4%) 8/77 (10.4%)	0.0046 0.3082 [°]
disease –	· /	29/179 (16.2%)	. ,	0.3082
	Omicron (n=441)	49/265 (18.5%)	13/176 (7.4%)	
	Original (n=1,847)	160/1,288 (12.4%)	34/559 (6.1%)	0.0001 ^C
Asthma	Gamma (n=2,040)	148/1,373 (10.8%)	37/667 (5.5%)	0.0002 ^C
	Delta (n=256)	23/181 (12.7%)	6/75 (8.0%)	0.3871
	Omicron (n=429)	26/257 (10.1%)	6/172 (3.5%)	0.0176 [°]
_	Original (n=1,887)	274/1,319 (20.8%)	65/568 (11.4%)	<0.0001 [°]
Diabetes	Gamma (n=2,134)	337/1,448 (23.3%)	77/686 (11.2%)	<0.0001 [°]
	Delta (n=267)	48/188 (25.5%)	8/79 (10.1%)	0.0079 [°]
	Omicron (n=446)	62/268 (23.1%)	10/178 (5.6%)	<0.0001 [°]
	Original (n=1,822)	181/1,263 (14.3%)	64/559 (11.4%)	0.1122
Obesity	Gamma (n=2,142)	368/1,451 (25.4%)	111/691 (16.1%)	<0.0001 [°]
·	Delta (n=259)	39/183 (21.3%)	8/76 (10.5%)	0.0610
	Omicron (n=425)	32/249 (12.9%)	10/176 (5.7%)	0.0229 ^c

8

^C Chi-square test was used to compare the groups, ^F Fisher exact test was used to compare the groups
 177

Among unvaccinated patients who were positive for the original SARS-CoV-2 variant, 178 179 the puerperal group, compared with the pregnant group, had a lower frequency of fever (OR: 0.76; 95% CI: 0.65 - 0.90), coughing (OR: 0.69; 95% CI: 0.58 - 0.83), vomiting 180 181 (OR: 0.47; 95% CI: 0.33 - 0.65), and ageusia (OR: 0.72; 95% CI: 0.53 - 0.97) and a higher frequency of respiratory discomfort (OR: 1.19; 95% CI: 1.01 – 1.39), SpO₂ < 182 95% on room air (OR: 1.70, 95% CI: 1.44 - 2.00), ICU admission (OR: 1.82; 95% CI 183 1.54 - 2.13), invasive respiratory support (OR: 2.62; 95% CI 2.13 - 3.22), and death 184 185 (OR: 2.48; 95% CI: 1.96 - 3.13) (Tables 2 and 3). Unvaccinated patients in the 186 puerperal group who had the Gamma variant had a lower frequency of fever (OR: 0.61; 95% CI: 0.50 - 0.76), coughing (OR: 0.56; 95% CI: 0.44 - 0.71), dyspnoea (OR: 0.75; 187 188 95% CI: 0.60 - 0.94), vomiting (OR: 0.49; 95% CI: 0.32 - 0.73), anosmia (OR: 0.60; 189 95% IC 0.43 – 0.82), and ageusia (OR: 0.69; 95% CI: 0.50 – 0.94); however, they were 190 more likely to be admitted to the ICU (OR: 1.58; 95% CI: 1.29 - 1.93), require invasive 191 respiratory support (OR: 2.17; 95% CI: 1.75 - 2.70), and die (OR: 1.99; 95% CI: 1.56 -192 2.53), compared with unvaccinated pregnant patients. There were no differences in symptoms, ICU admission, requirement for invasive respiratory support, or death 193 194 between the two groups among unvaccinated patients with the Delta variant. Unvaccinated patients in the puerperal group with the Omicron variant had a lower 195 frequency of vomiting (OR: 0.23; 95% CI: 0.03 - 0.98) and a higher frequency of ICU 196 admission (OR: 2.61: 95% CI: 1.25 – 5.38) and invasive respiratory support (OR: 3.09: 197 198 95% CI: 1.12 – 8.50), compared with unvaccinated pregnant patients with the Omicron 199 variant.

200 Among vaccinated patients with the Gamma variant, patients in the puerperal group 201 were more likely to die than those in the pregnant group (OR: 2.58; 95% CI: 1.03 -202 6.06). Among vaccinated patients with the Delta variant, symptoms, ICU admission, 203 requirement for invasive respiratory support, and death rate were not significantly different between the pregnant and puerperal groups. Patients in the puerperal group 204 205 with the Omicron variant who were vaccinated had a lower frequency of fever (OR: 206 0.43. 95% CI: 0.28 – 0.66) and vomiting (OR: 0.35; 95% CI: 0.12 – 0.85) and a higher 207 frequency of dyspnoea (OR: 1.64; 95% CI: 1.07 - 2.50), SpO₂ < 95% on room air (OR: 208 1.97; 95% CI: 1.20 - 3.22), ICU admission (OR: 1.91; 95% CI: 1.13 - 3.17), and 209 invasive respiratory support (OR: 2.88; 95% CI: 1.34 – 6.21), compared with those in 210 the pregnant group.

- 211
- 212

Table 2. Signs and symptoms of COVID-19 in pregnant and postpartum women

			Unvaccinated	I	Vacci	nated (at leas	t one dose)
Signs and symptoms	Variant	Pregnant	Puerperal	Puerperal vs. Pregnant OR (95% CI)	Pregnant	Puerperal	Puerperal vs. Pregnant OR (95% CI)

	Original	2,283/3,345	500/805	0.76	_	_	_
-	(n=4,150)	(68.3%)	(62.1%)	(0.65 – 0.90)			
	Gamma	1,283/1,995	241/459	0.61	204/321	32/64	0.57
Fever	(n=2,839)	(64.3%)	(52.5%)	(0.50 – 0.76)	(63.6%)	(50.0%)	(0.32 – 1.02)
-	Delta	131/206	30/47	1.01	146/237	20/39	0.66
	(n=529)	(63.6%)	(63.8%)	(0.50 - 2.09)	(61.6%)	(51.3%)	(0.31 – 1.38)
-	Omicron	108/190	28/66	0.56	244/491	40/134	0.43
	(n=881)	(56.8%)	(42.4%)	(0.30 - 1.02)	(49.7%)	(29.9%)	(0.28 – 0.66)
	Original	2,674/3,454	576/818	0.69			
	(n=4,272)	(77.4%)	(70.4%)	(0.58 - 0.83)	-	-	-
-	Gamma	1,689/2,079	335/473	0.56	273/331	51/69	0.60
. .	(n=2,952)	(81.2%)	(70.8%)	(0.44 - 0.71)	(82.5%)	(73.9%)	(0.32 – 1.17)
Cough	Delta	175/223	40/52	0.91	194/252	28/41	0.64
	(n=568)	(78.5%)	(76.9%)	(0.43 - 2.06)	(77.0%)	(68.3%)	(0.30 – 1.45)
-	Omicron	140/205	43/68	0.80	359/529	96/151	0.83
	(n=953)	(68.3%)	(63.2%)	(0.43 - 1.49)	(67.9%)	(63.6%)	(0.56 – 1.23)
	Original	825/2,960	182/696	0.92	(,0)	(/0)	(
	(n=3,656)	(27.9%)	(26.1%)	(0.76 – 1.11)	-	-	-
-	Gamma	488/1,810	96/414	0.82	71/281	13/62	0.79
Sore throat	(n=2,567)	(27.0%)	(23.2%)	(0.63 – 1.06)	(25.3%)	(21.0%)	(0.37 – 1.58)
oore throat	Delta	48/186	8/45	0.62	69/222	9/33	0.83
	(n=486)			(0.23 – 1.48)		9/33 (27.3%)	
-	\ <i>\</i>	(25.8%)	(17.8%)		(31.1%)	· · ·	(0.32 – 1.97)
	Omicron	70/182	15/58 (25.0%)	0.56	177/462	40/131 (20.5%)	0.71
	(n=833)	(38.5%)	(25.9%)	(0.27 – 1.12)	(38.3%)	(30.5%)	(0.45 – 1.09)
	Original	2,024/3,305	467/781	0.94	-	-	-
_	(n=4,086)	(61.2%)	(59.8%)	(0.80 – 1.11)	004/000	4.4/0.0	0.00
	Gamma	1,493/2,051	314/470	0.75	231/326	44/66	0.82
Dyspnoea	(n=2,913)	(72.8%)	(66.8%)	(0.60 - 0.94)	(70.9%)	(66.7%)	(0.45 – 1.52)
	Delta	149/216	36/51	1.08	147/238	20/40	0.62
-	(n=545)	(69.0%)	(70.6%)	(0.53 – 2.27)	(61.8%)	(50.0%)	(0.29 – 1.29)
	Omicron	58/174	16/61	0.71	117/443	52/140	1.64
	(n=818)	(33.3%)	(26.2%)	(0.35 – 1.42)	(26.4%)	(37.1%)	(1.07 – 2.50)
	Original	1,565/3,123	413/759	1.19	-	-	-
-	(n=3,882)	(50.1%)	(54.4%)	(1.01 – 1.39)			
Respiratory	Gamma	1,143/1,944	267/448	1.03	168/303	35/67	0.88
discomfort	(n=2,762)	(58.8%)	(59.6%)	(0.83 -1.28)	(55.4%)	(52.2%)	(0.50 – 1.55)
	Delta	113/203	22/47	0.70	105/222	11/38	0.46
_	(n=510)	(55.7%)	(46.8%)	(0.35 – 1.39)	(47.3%)	(28.9%)	(0.19 – 1.00)
	Omicron	42/170	14/60	0.92	127/438	42/139	1.06
	(n=807)	(24.7%)	(23.3%)	(0.43 – 1.92)	(29.0%)	(30.2%)	(0.68 – 1.63)
	Original	1,020/3,043	340/737	1.70	_		
	(n=3,780)	(33.5%)	(46.1%)	(1.44 – 2.00)	-	-	-
	Gamma	1,120/1,964	264/451	1.06	163/299	34/66	0.89
SpO ₂ <95%	(n=2,780)	(57.0%)	(58.5%)	(0.86 – 1.32)	(54.5%)	(51.5%)	(0.50 – 1.57)
	Delta	112/205	32/47	1.77	93/227	17/38	1.16
	(n=517)	(54.6%)	(68.1%)	(0.86 - 3.74)	(41.0%)	(44.7%)	(0.55 – 2.46)
	Omicron	31/170	12/57	1.19	67/426	35/130	1.97
	(n=783)	(18.2%)	(21.1%)	(0.51 – 2.63)	(15.7%)	(26.9%)	(1.20 – 3.22)
	Original	404/2,879	74/660	0.77			
	(n=3,539)	(14.0%)	(11.2%)	(0.58 - 1.01)	-	-	-
	Gamma	220/1,761	37/406	0.70	25/271	7/63	1.23
Dia 1	(n=2,501)	(12.5%)	(9.1%)	(0.47 - 1.02)	(9.2%)	(11.1%)	(0.43 – 3.11)
Diarrhoea	Delta	17/183	5/44	1.25	22/212	1/33	0.27
	(n=472)	(9.3%)	(11.4%)	(0.34 - 3.82)	(10.4%)	(3.0%)	(0.01 – 1.80)
	Omicron	13/167	2/56	0.44	22/416	7/122	1.09
	(n=583)	(7.8%)	(3.6%)	(0.05 – 2.04)	(5.3%)	(5.7%)	(0.38 – 2.73)
	Original	399/2,884	46/655	0.47	(0.070)	(3.170)	(0.00 2.10)
Vomiting	Ginginai	000/2,004			-	-	_
Vomiting	(n=3 530)	(13.8%)	(7 0%)	(0.33 - 0.65)			_
Vomiting	(n=3,539) Gamma	(13.8%) 249/1,771	(7.0%) 30/407	(0.33 – 0.65) 0.49	35/271	7/61	0.87

10

	(- - (-)		(T
	(n=2,510)	(14.1%)	(7.4%)	(0.32 – 0.73)	(12.9%)	(11.5%)	(0.31 – 214)	
	Delta	21/182	1/44	0.18	24/211	2/33	0.5915	1
	(n=470)	(11.5%)	(2.3%)	(0.00 - 1.18)	(11.4%)	(6.1%)	(0.06 – 2.21)	
	Omicron	24/170	2/55	0.23	54/423	6/122	^{0.3} 216	
	(n=770)	(14.1%)	(3.6%)	(0.03 – 0.98)	(12.8%)	(4.9%)	(0.12 – 0.85)	
	Original	159/1,562	26/324	0.77			_217	-
	(n=1,886)	(10.2%)	(8.0%)	(0.48 – 1.20)	-	-	-	
Abdominal	Gamma	177/1,750	35/401	0.85	29/263	3/62	0.41	
pain	(n=2,476)	(10.1%)	(8.7%)	(0.56 – 1.25)	(11.0%)	(4.8%)	(0.08 – 1.40)	
pain	Delta	23/181	2/44	0.33	21/208	4/33	1.23	-
	(n=466)	(12.7%)	(4.5%)	(0.04 - 1.42)	(10.1%)	(12.1%)	(0.29 - 4.02)	
	Omicron	18/168	3/55	0.48	56/415	9/123	0.51	-
	(n=761)	(10.7%)	(5.5%)	(0.09 – 1.75)	(13.5%)	(7.3%)	(0.21 – 1.07)	
	Original	394/1,595	71/338	0.81	_	_	_	
Fatigue	(n=1,933)	(24.7%)	(21.0%)	(0.60 - 1.08)	-	-		
	Gamma	640/1,820	127/411	0.82	113/279	21/66	0.69	
	(n=2,576)	(35.2%)	(30.9%)	(0.65 – 1.04)	(40.5%)	(31.8%)	(0.37 – 1.25)	
	Delta	52/187	17/45	1.57	62/213	7/33	0.66	I
	(n=478)	(27.8%)	(37.8%)	(0.74 – 3.27)	(29.1%)	(21.2%)	(0.23 – 1.66)	
	Omicron	38/168	9/58	0.63	75/417	24/125	1.08	
	(n=768)	(22.6%)	(15.5%)	(0.25 – 1.45)	(18.0%)	(19.2%)	(0.62 – 1.84)	Abbr
	Original	442/1,636	78/348	0.78	_	-	_	ation
	(n=1,984)	(27.0%)	(22.4%)	(0.58 – 1.03)	-	-	-	OR,
	Gamma	373/1,778	55/401	0.60	59/275	10/63	0.69	Odds
Anosmia	(n=2,517)	(21.0%)	(13.7%)	(0.43 – 0.82)	(21.5%)	(15.9%)	(0.30 – 1.48)	Ratio
Allosinid	Delta	37/180	4/44	0.39	44/210	6/34	0.81	95%
	(n=468)	(20.6%)	(9.1%)	(0.09 - 1.18)	(21.0%)	(17.6%)	(0.26 – 2.16)	CI,
	Omicron	7/164	2/54	0.86	14/407	2/123	0.46	95%
	(n=748)	(4.3%)	(3.7%)	(0.08 – 4.73)	(3.4%)	(1.6%)	(0.05 – 2.07)	
	Original	400/1,615	66/343	0.72	_	_]	confi
	(n=1,958)	(24.8%)	(19.2%)	(0.53 – 0.97)	-	-	-	nce
	Gamma	332/1,777	55/403	0.69	64/276	8/61	0.50	inter
Ageusia	(n=2,517)	(18.7%)	(13.6%)	(0.50 - 0.94)	(23.2%)	(13.1%)	(0.20 – 1.13)	SpO
	Delta	37/178	5/44	0.49	42/211	7/35	1.01	oxyg
	(n=468)	(20.8%)	(11.4%)	(0.14 – 1.37)	(19.9%)	(20.0%)	(0.35 – 2.57)	satur
	Omicron	7/163	1/54	0.42 (18/406	3/123	0.54	on in
	(n=746)	(4.3%)	(1.9%)	0.01 - 3.41)	(4.4%)	(2.4%)	(0.10 – 1.89)	room

241

air.

242

243

Table 3. Outcomes of pregnant and postpartum women with COVID-19

		Unvaccinated			Vaccinated (with at least one dose)			
Outcome	Variant	Pregnant	Puerperal	Puerperal vs. Pregnant OR (95% CI)	Pregnant	Puerperal	Puerperal vs. Pregnant OR (95% Cl)	
	Original	833/3,566	310/870	1.82	_	_	_	
ICU admission	(n=4,436)	(23.4%)	(35.6%)	(1.54 – 2.13)	-	-	-	
	Gamma	795/2,157	235/490	1.58	91/334	28/70	1.78	
	(n=3,051)	(36.9%)	(48.0%)	(1.29 – 1.93)	(27.2%)	(40.0%)	(1.00 – 3.13)	
	Delta	90/225	26/51	1.56	75/256	16/47	1.24	
(n=9,202)	(n=579)	(40.0%)	(51.0%)	(0.81 – 3.01)	(29.3%)	(34.0%)	(0.60 - 2.51)	
	Omicron	23/257	18/88	2.61	59/623	28/168	1.91	
	(n=1,136)	(8.9%)	(20.5%)	(1.25 – 5.38)	(9.5%)	(16.7%)	(1.13 – 3.17)	
Invasive	Original	300/3,389	172/848	2.62				
invasive	(n=4,237)	(8.9%)	(20.3%)	(2.13 – 3.22)	-	-	-	

1	4
ж.	ж.

respiratory	Gamma	411/2,105	163/472	2.17	39/319	12/68	1.54	
support	(n=2,964)	(19.5%)	(34.5%)	(1.75 – 2.70)	(12.2%)	(17.6%)	(0.76 – 3.12)	
(n=8,904)	Delta	34/225	11/51	1.54	20/254	4/46	1.11	
	(n=576)	(15.1%)	(21.6%)	(0.72 – 3.30)	(7.9%)	(8.7%)	(0.36 - 3.42)	
	Omicron	8/252	8/87	3.09	16/619	12/169	2.88	
	(n=1127)	(3.2%)	(9.2%)	(1.12 – 8.50)	(2.6%)	(7.1%)	(1.34 – 6.21)	
	Original	231/3,563	130/886	2.48	_	_	_	
	(n=4,449)	(6.5%)	(14.7%)	(1.96 – 3.13)	-	-	-	
	Gamma	325/2,117	128/483	1.99	22/341	10/66	2.58	
Death	(n=3,007)	(15.4%)	(26.5%)	(1.56 – 2.53)	(6.5%)	(15.2%)	(1.03 – 6.06)	
(n=9,206)	Delta	23/222	8/48	1.73	7/243	1/46	0.75	
	(n=559)	(10.4%)	(16.7%)	(0.62 – 4.36)	(2.9%)	(2.2%)	(0.02 - 6.07)	
	Omicron	6/267	2/94	0.95	7/659	6/171	3.38	
	(n=1191)	(2.2%)	(2.1%)	(0.09 – 5.41)	(1.1%)	(3.5%)	(0.93 – 11.93)	

Abbreviations: OR, Odds Ratio; %CI, 95% confidence interval; ICU, Intensive care unit

247

248 **DISCUSSION**

In this study, the clinical findings and outcomes of pregnant and postpartum women withCOVID-19 differed. These differences were influenced by the predominant VOCs at the

time of diagnosis (original, Gamma, Delta, and Omicron) and patient vaccination status.

252

253 postpartum women

254 When the COVID-19 pandemic began in 2020, it was believed that pregnant and 255 puerperal women were not at a higher risk of adverse outcomes or death than the non-256 obstetric population.[3, 4, 24-27] However, updated studies reported higher rates of 257 invasive ventilation, ICU admissions, and death due to COVID-19 in the obstetric 258 population.[6-8, 10, 28, 29] Differences in clinical findings and outcomes between 259 pregnant and postpartum women are unclear, as previous studies regarding these 260 differences included non-hospitalized patients in whom a COVID-19 diagnosis was not 261 confirmed using RT-PCR.[8-11]

Another previous study compared the clinical findings and outcomes of pregnant, puerperal, and non-pregnant nor puerperal women aged 10 to 49 years with COVID-19 from the beginning of the pandemic until 2 January 2021. This previous study used propensity score matching and found that puerperal women were more likely than pregnant women to be admitted to the ICU (OR: 1.97), require invasive respiratory support (OR: 2.71), and die (OR: 2.51).[15]

The three delays model can be used to explain why postpartum women had worse 268 269 prognoses than pregnant women in this study.[30] During the postpartum period, 270 women may delay seeking medical assistance, as they focus on taking care of their 271 new-born, ignoring their own health care.[31, 32] The risk of thromboembolism 272 increases during the postpartum period as well as in patients with COVID-19.[33-37] As 273 the SIVEP-Gripe does not provide information regarding the date of delivery or the 274 gestational age upon diagnosis, some patients in the puerperal group may have been 275 infected with SARS-CoV-2 during pregnancy that progressed to SARS after delivery. In 276 addition, pregnant women with SARS may terminate their pregnancy as a therapeutic 277 measure and may die during the puerperal period. Caesarean sections account for 278 more than 57% of deliveries in Brazil and are even more frequent among patients with 279 severe COVID-19, which may increase the risk of maternal mortality in this 280 population.[37-40]

Among the unvaccinated patients in this study, those in the puerperal group had worse prognosis than those in the pregnant group for each VOC. In the puerperal group, 35.6%, 48.0%, 51.0%, and 20.5% of unvaccinated patients with the original, Gamma, Delta, and Omicron variants, respectively, were admitted to the ICU; 20.3%, 34.5%, 21.6%, and 9.2%, respectively, required invasive ventilation; and 14.7%, 26.5%, 16.7%, and 2.1%, respectively, died. The mortality rate was significantly lower in unvaccinated pregnant patients, with the exception of patients with the Omicron variant.

- 288 Studies including the general population have reported that different VOCs and 289 vaccination statuses affect the clinical symptoms and outcomes of patients with COVID-290 19.[41-42] A review concluded that the Alpha, Beta, and Gamma variants were 291 associated with higher risks of hospitalization and ICU admission, compared with the 292 original variant and that the Beta variant had the highest risk of ICU admission.[43] A 293 meta-analysis reported higher risks of hospitalization, ICU admission, and mortality for 294 patients infected with the Beta and Delta variants, compared with those infected with the 295 Alpha and Gamma variants. The meta-analysis also concluded that all SARS-CoV-2 296 VOCs are associated with a higher risk of severe outcomes, compared with the original 297 SARS-CoV-2 variant.[44]
- 298 In this study, postpartum patients were less likely to have comorbidities, although the 299 comorbidities varied between the VOC subgroups. Patients in the puerperal group also presented with different clinical findings based on the VOC and their vaccination status. 300 301 Patients in the puerperal group who were unvaccinated were more likely to have an SpO₂ < 95% on room air. This was true in all VOC subgroups. Unvaccinated patients in 302 303 the puerperal group with the original, Gamma, and Omicron were more likely to be 304 admitted to the ICU and to require invasive ventilatory support, and those with the 305 original and Gamma variants were more likely to die.
- Among the vaccinated puerperal patients, those in Omicron variant subgroup had a higher risk of having an $SpO_2 < 95\%$ on room air. Vaccinated puerperal patients in the Omicron subgroup also had a higher risk of ICU admission and requiring invasive ventilatory support. Those in the Gamma subgroup had an increased risk of death. These findings suggest that puerperal women have a higher risk of severe outcomes than pregnant women, especially when unvaccinated.
- Previous observational studies and surveillance data regarding vaccination during pregnancy are reassuring. Most patients in the previous studies were administered the Pfizer/BioNTech or Moderna vaccines, and no adverse outcomes or side effects of vaccination during pregnancy were reported.[45-48] In Brazil, pregnant women are administered the Sinovac/Butantan and Pfizer/Wyeth vaccines.[49] In hospitalized

317 pregnant and postpartum patients with severe COVID-19, those who received two doses of a COVID-19 vaccine had a 46% reduction in the odds of ICU admission, an 318 319 81% reduction in the odds of requiring invasive ventilatory support, and an 80% 320 reduction in the odds of death, compared with those who did not receive any COVID-19 321 vaccination.[19] Among the general population, several studies have indicated that COVID-19 vaccination protects against severe outcomes caused by SARS-CoV-2 322 323 variants, including the Omicron variant.[50-52] The results of the current study support 324 these previous findings and suggest that vaccines effectively reduce adverse outcomes 325 including ICU admission, the requirement for invasive ventilatory support, and death in 326 pregnant and puerperal patients. Therefore, vaccination is an important public health 327 strategy globally, and pregnant and postpartum women should be included in 328 randomized clinical trials.[19, 53].

This study has several strengths, including the use of a large dataset with nationwide coverage and no duplicates that included hospitalized obstetric patients with COVID-19 confirmed via RT-PCR, VOC data, and vaccination status. Similar studies neither reported these data nor divided the obstetric population into pregnant and puerperal groups.

- 334 However, this study has limitations, including its retrospective nature based on a secondary database analysis. Although reporting COVID-19-related hospital admissions 335 336 is compulsory in Brazil, it is not guaranteed that all patients with COVID-19 who were 337 hospitalized were included in the database. Bias due to missing or inaccurate data 338 cannot be ruled out. Asymptomatic or mildly symptomatic patients are not reported in 339 the SIVEP-Gripe; therefore, an analysis of the non-hospitalized population was not 340 possible. In addition, the database used in this study does not include information 341 regarding other obstetric variables such as gestational age, delivery mode, date of birth, 342 comorbidities, week of pregnancy at diagnosis, and perinatal data. As it is an 343 anonymous database, the data cannot be linked with the public database of birth 344 registers and mode of delivery.
- As postpartum women have higher risks of developing severe forms of COVID-19, especially when unvaccinated, health care strategies to implement vaccination and manage postpartum patients with COVID-19 are necessary. The risk of severe COVID-19 in puerperal patients should not be underestimated, and health care workers should closely monitor all postpartum women infected with SARS-CoV-2, especially those who are not vaccinated. The vaccination of pregnant and postpartum patients should become a public health priority.
- 352

353 Acknowledgements

- 354 None
- 355 **Competing interests**
- 356 The authors have declared that no competing interests exist.

357 Funding

This work was supported, in whole or in part, by the Bill & Melinda Gates Foundation 358 [INV-027961]. Under the grant conditions of the Foundation, a Creative Commons 359 Attribution 4.0 Generic License has already been assigned to the Author Accepted 360 361 Manuscript version that might arise from this submission. This work is also funded by 362 CNPq (Award Number: 445881/2020-8) and FAPES (Award Number: 44437.699.40413.22122020). The funders had no role in study design, data collection 363 364 and analysis, decision to publish, or preparation of the manuscript.

365 Data availability

- The data that support the findings of this study are available in GitHub repository at
- 367 <u>https://github.com/observatorioobstetrico/COVID-19-impact-of-original-Gamma-Delta-</u>
- 368 <u>and-Omicron-variants-of-SARS-CoV-2-in-vaccinated-and-unv</u>. These data were derived
- 369 from the following resources available in the public domain:
- 370 https://opendatasus.saude.gov.br/dataset/srag-2020 and
- 371 <u>https://opendatasus.saude.gov.br/dataset/srag-2021-e-2022</u> obtained on 25 July 2022.
- 372

373 **REFERENCES**

- 374
- 1 World Health Organization. WHO Director-General's opening remarks at the media briefing
- on COVID-19 11 March 2020. Accessed: 23 March 2022. Available from:
- 377 https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-
- 378 remarks-at-the-media-briefing-on-covid-19---11-march-2020
- World Health Organization. WHO COVID-19 Dashboard. Accessed: 26 August 2022. Available
 from: https://covid19.who.int/
- 381 3 Zaigham M, Andersson O. Maternal and perinatal outcomes with COVID-19: A systematic
- review of 108 pregnancies. *Acta Obstet Gynecol Scand* 2020;99:823–9.
- 4 Kasraeian M, Zare M, Vafaei H, et al. COVID-19 pneumonia and pregnancy; a systematic review and meta-analysis. *J Matern Fetal Neonatal Med* 2022;35:1652–9.
- 5 Mullins E, Evans D, Viner RM, et al. Coronavirus in pregnancy and delivery: rapid review.
 Ultrasound Obstet Gynecol 2020;55:586–92.
- 6 Badr DA, Mattern J, Carlin A, et al. Are clinical outcomes worse for pregnant women at ≥20
- weeks' gestation infected with coronavirus disease 2019? A multicenter case-control study with
- propensity score matching. *Am J Obstet Gynecol* 2020;223:764–68.
- 390 7 Sentilhes L, De Marcillac F, Jouffrieau C, et al. Coronavirus disease 2019 in pregnancy was
- associated with maternal morbidity and preterm birth. *Am J Obstet Gynecol* 2020;223:914.e1–
 15.

- 8 Zambrano LD, Ellington S, Strid P, et al. Update: Characteristics of Symptomatic Women of
- 394 Reproductive Age with Laboratory-Confirmed SARS-CoV-2 Infection by Pregnancy Status -
- United States, January 22-October 3, 2020. *MMWR Morb Mortal Wkly Rep* 2020;69:1641–7.
- 9 Allotey J, Stallings E, Bonet M, et al. Clinical manifestations, risk factors, and maternal and
 perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and
- 398 meta-analysis. *BMJ* 2020;370:m3320.
- 10 Martinez-Portilla RJ, Sotiriadis A, Chatzakis C, et al. Pregnant women with SARS-CoV-2
- 400 infection are at higher risk of death and pneumonia: propensity score matched analysis of a
- 401 nationwide prospective cohort (COV19Mx). *Ultrasound Obstet Gynecol* 2021;57:224–31.
- 402 11 Rozo N, Valencia D, Newton SM, et al. Severity of illness by pregnancy status among
- 403 laboratory-confirmed SARS-CoV-2 infections occurring in reproductive-aged women in
 404 Colombia *Paediatr Perinat Epidemiol* 2022;36:456–65. 2021
- 405 12 World Health Organization. Tracking SARS-CoV-2 variants. Accessed: 21 May 2022. Available
 406 from: http://who.int/en/activities/tracking-SARS-CoV-2-variants/
- 407 13 FIOCRUZ. FIOCRUZ: Genomic Network. Accessed: 22 May 2022. Available from:
 408 http://www.genomahcov.fiocruz.br/
- 409 14 Takemoto M, Menezes MO, Andreucci CB, et al. Clinical characteristics and risk factors for
- 410 mortality in obstetric patients with severe COVID-19 in Brazil: a surveillance database analysis.
- 411 *BJOG* 2020;127:1618–26.
- 412 15 Serra FE, Francisco RPV, de Rossi P, et al. COVID-19 outcomes in hospitalized puerperal,
 413 pregnant, and neither pregnant nor puerperal women. *PLoS One* 2021;16:e0259911.
- 414 16 Francisco R, Lacerda L, Rodrigues AS. Obstetric Observatory BRAZIL COVID-19: 1031
- 415 maternal deaths because of COVID-19 and the unequal access to health care services. *Clinics*
- 416 *(Sao Paulo)* 2021;76:e3120.
- 417 17 Gonçalves BMM, Franco RPV, Rodrigues AS. Maternal mortality associated with COVID-19 in
- 418 Brazil in 2020 and 2021: Comparison with non-pregnant women and men. *PLoS One* 419 2021;16:e0261492.
- 420 18 Brazil. Ministry of Health. Department of Health Surveillance. Department of Immunization
- 421 and Transmitted Diseases. General Coordination of the National immunization Program: NOTA
- 422 TÉCNICA Nº 467/2021-CGPNI/DEIDT/SVS/MS. Accessed: 22 May 2022. Available from:
- 423 https://www.gov.br/saude/pt-br/media/pdf/2021/abril/27/nota-tecnica-467-2021-cgpni-deidt-
- 424 svs-ms.pdf
- 425 19 Kalafat E, Heath P, Prasad S, et al. COVID-19 vaccination in pregnancy. *Am J Obstet Gynecol*426 2022;227:136–47.

- 427 20 de Freitas Paganoti C, Alkmin da Costa R, Papageorghiou AT, et al. COVID-19 Vaccines Confer
- 428 Protection in Hospitalized Pregnant and Postpartum Women with Severe COVID-19: A
- 429 Retrospective Cohort Study. *Vaccines (Basel)* 2022;10:749.
- 430 21 Brazil. Ministry of Health. Definition of Case and Notification. Accessed: 4 April 2021.
- 431 Available from: https://www.gov.br/saude/pt-br/coronavirus/artigos/definicao-e-casos-
- 432 suspeitos
- 433 22 Brazil. Ministry of Health. SINAN Notifiable Diseases Information System. Epidemiological
- 434 Calendar 2022. Accessed: 30 August 2022. Available from:
- 435 http://www.portalsinan.saude.gov.br/calendario-epidemiologico
- 436 23 R Core Team. R: A language and environment for statistical computing. R Foundation for
- 437 Statistical Computing, Vienna, Austria, 2020. Version 4.1.3. Accessed on: 30 July 2022. Available
- 438 from: https://www.r-project.org/.
- 439 24 Chen H, Guo J, Wang C, et al. Clinical characteristics, and intrauterine vertical transmission
- 440 potential of COVID-19 infection in nine pregnant women: a retrospective review of medical
- 441 records. *Lancet* 2020;395:809–15.
- 442 25 Di Toro F, Gjoka M, Di Lorenzo G, et al. Impact of COVID-19 on maternal and neonatal 443 outcomes: a systematic review and meta-analysis. *Clin Microbiol Infect* 2021;27:36–46.
- 26 Elshafeey F, Magdi R, Hindi N, et al. A systematic scoping review of COVID-19 during
 pregnancy and childbirth. *Int J Gynaecol Obstet* 2020;150:47–52.
- 446 27 Huntley BJF, Huntley ES, Di Mascio D, et al. Rates of Maternal and Perinatal Mortality and
- 447 Vertical Transmission in Pregnancies Complicated by Severe Acute Respiratory Syndrome
- 448 Coronavirus 2 (SARS-Co-V-2) Infection: A Systematic Review. *Obstet Gynecol* 2020;136:303–12.
- 28 Hantoushzadeh S, Shamshirsaz AA, Aleyasin A, et al. Maternal death due to COVID-19. Am J
 Obstet Gynecol 2020;223:109.e1–16.
- 451 29 Collin J, Byström E, Carnahan A, et al. Public Health Agency of Sweden's Brief Report:
- 452 Pregnant and postpartum women with severe acute respiratory syndrome coronavirus 2
- 453 infection in intensive care in Sweden. *Acta Obstet Gynecol Scand* 2020;99:819–22.
- 30 Thaddeus S, Maine D. Too far to walk: maternal mortality in context. *Soc Sci Med*1994;38:1091–110.
- 456 31 Finlayson K, Crossland N, Bonet M, et al. What matters to women in the postnatal period: A
 457 meta-synthesis of qualitative studies. *PLoS One* 2020;15:e0231415.
- 458 32 Pacagnella RC, Cecatti JG, Parpinelli MA, et al. Delays in receiving obstetric care and poor
- 459 maternal outcomes: results from a national multicentre cross-sectional study. BMC Pregnancy
- 460 *Childbirth* 2014;14:159.

- 33 Kamel H, Navi BB, Sriram N, et al. Risk of a thrombotic event after the 6-week postpartum
 period. *N Engl J Med* 2014;370:1307–15.
- 463 34 Helms J, Tacquard C, Severac F, et al. High risk of thrombosis in patients with severe SARS-
- 464 CoV-2 infection: a multicenter prospective cohort study. *Intensive Care Med* 2020;46:1089–98.
- 465 35 Tang N, Li D, Wang X, et al. Abnormal coagulation parameters are associated with poor
- 466 prognosis in patients with novel coronavirus pneumonia. *J Thromb Haemost* 2020;18:844–7.
- 467 36 Katz D, Beilin Y. Disorders of coagulation in pregnancy. *Br J Anaesth* 2015;115:75–88.
- 468 37 Sobhy S, Arroyo-Manzano D, Murugesu N, et al. Maternal and perinatal mortality and
- 469 complications associated with caesarean section in low-income and middle-income countries: a 470 systematic review and meta-analysis. *Lancet* 2019;393:1973–82.
- 471 38 Nahshon C, Bitterman A, Haddad R, et al. Hazardous Postoperative Outcomes of Unexpected
- 472 COVID-19 Infected Patients: A Call for Global Consideration of Sampling all Asymptomatic
- 473 Patients Before Surgical Treatment. *World J Surg* 2020;44:2477–81.
- 474 39 Aminian A, Safari S, Razeghian-Jahromi A, et al. COVID-19 Outbreak and Surgical Practice:
 475 Unexpected Fatality in Perioperative Period. *Ann Surg* 2020;272:e27–9.
- 40 Brazil. Ministry of Health, 2020. DATASUS. Live Birth Information System SINASC. Accessed:
 23 July 2022. Available from: http://tabnet.datasus.gov.br/cgi/tabcgi.exe?sinasc/cnv/nvuf.def
- 478 41 Loconsole D, Centrone F, Morcavallo C, et al. Changing Features of COVID-19:
- 479 Characteristics of Infections with the SARS-CoV-2 Delta (B.1.617.2) and Alpha (B.1.1.7) Variants
- 480 in Southern Italy. *Vaccines* 2021;9:1354.
- 481 42 Wang S, Zou X, Li Z, et al. Analysis of Clinical Characteristics and Virus Strains Variation of
 482 Patients Infected With SARS-CoV-2 in Jiangsu Province-A Retrospective Study. *Front Public*483 *Health* 2021;9:791600.
- 484 43 Cantón R, De Lucas Ramos P, García-Botella A, et al. New variants of SARS-CoV-2. *Rev Esp*485 *Quimioter*2021;34:419–28.
- 486 44 Lin L, Liu Y, Tang X, et al. The Disease Severity and Clinical Outcomes of the SARS-CoV-2
 487 Variants of Concern. *Front Public Health* 2021;9:775224.
- 488 45 Gray KJ, Bordt EA, Atyeo C, et al. Coronavirus disease 2019 vaccine response in pregnant and
 489 lactating women: a cohort study. *Am J Obstet Gynecol* 2021;225:303.e1–17.
- 46 Mackin DW, Walker SP. The historical aspects of vaccination in pregnancy. *Best Pract Res Clin Obstet Gynaecol* 2021;76:13–22.

- 47 Blakeway H, Prasad S, Kalafat E, et al. COVID-19 vaccination during pregnancy: coverage and
 safety. Am J Obstet Gynecol 2022;226:236.e1–14.
- 494 48 Lipkind HS, Vazquez-Benitez G, DeSilva M, et al. Receipt of COVID-19 Vaccine During
- 495 Pregnancy and Preterm or Small-for-Gestational-Age at Birth Eight Integrated Health Care
- 496 Organizations, United States, December 15, 2020-July 22, 2021. MMWR Morb Mortal Wkly Rep
- 497 2022;71:26–30.
- 498 49 Brazil. Ministry of Health. Department of Health Surveillance. Department of Immunization
- 499 and Transmitted Diseases. General Coordination of the National immunization Program: Nota
- 500 *Técnica* № 651/2021-CGPNI/DEIDT/SVS/MS. Accessed: 30 July 2022. Available from:
- 501 https://www.gov.br/saude/pt-br/media/pdf/2021/maio/19/nota-tecnica-651-2021-cgpni-
- 502 deidt-svs-ms.pdf
- 503 50 León TM, Dorabawila V, Nelson L, et al. COVID-19 cases and hospitalizations by COVID-19
- vaccination status and previous COVID-19 diagnosis—California and New York, May–November
 2021. MMWR Morb Mortal Wkly Rep 2022;71:125–31.
- 505 2021. MMWR Morb Mortal Wkly Rep 2022;71:125–31.
- 506 51 Thompson MG, Natarajan K, Irving SA, et al. Effectiveness of a third dose of mRNA vaccines
- against COVID-19–associated emergency department and urgent care encounters and
- 508 hospitalizations among adults during periods of Delta and Omicron variant predominance—
- 509 VISION Network, 10 states, August 2021–January 2022. *MMWR Morb Mortal Wkly Rep*
- 510 2022;71:139–45.
- 511 52 Danza P, Koo TH, Haddix M, et al. SARS-CoV-2 Infection and Hospitalization Among Adults
- 512 Aged ≥18 Years, by Vaccination Status, Before and During SARS-CoV-2 B.1.1.529 (Omicron)
- 513 Variant Predominance Los Angeles County, California, November 7, 2021-January 8,
- 514 2022. *MMWR Morb Mortal Wkly Rep* 2022;71:177–81.
- 53 Beigi RH, Krubiner C, Jamieson DJ, et al. The need for inclusion of pregnant women in COVID19 vaccine trials. *Vaccine* 2021;39:868–70.
- 517
- 518
- 210
- 519

520 Figure legend

521 Figure 1. Study Profile: case selection flowchart

- 522 Abbreviations: SIVEP-Gripe: System of Information about Epidemiological
- 523 Surveillance of Influenza; SARS: severe acute respiratory syndrome; COVID-19:
- 524 Coronavirus disease 2019; RT-PCR: polymerase chain reaction

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

